The court decision follows a request by the US department to put the motion against Ranbaxy in abeyance for a reasonable period, a source close to Ranbaxy said.
Ranbaxy had informed the court, in a response on July 15, that it withheld some privileged information on the tests carried out at its facility at Paonta Sahib in Himachal Pradesh and expressed its willingness to share all information with the US government in a month's time.
The company's response prompted the US government counsel to request the court on July 28to put the motion in abeyance.
"Inconsideration of the pace and apparent agreement to produce the Parexel documents, the United States requests that the Court hold the motion in abeyance for a reasonable period", the reply had said.
Thegovernment also indicated its intention to withdraw the motion after Ranbaxy submits all the documents.
In a separate development, Ranbaxy said the World Health Organisation (WHO), Geneva, has included the company's low cost version of AIDS medicine Abacavir 300 mg tablets in its pre-qualificationlist.
This medicine will be manufactured at Ranbaxy's WHO pre-qualifiedmanufacturing site at Paonta Sahib, the company said.